Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ERYTHROMYCIN ESTOLATE

All products: not a benefit

Other products in the same Health Canada class (J01FA) — coverage varies; not interchangeable

  • Azithromycin (Zithromax): general benefit, Limited Use 549, Not a benefit
  • Clarithromycin (Biaxin XL): general benefit, Not a benefit
  • Erythromycin base (Erythromid): general benefit, Not a benefit
  • Erythromycin ethylsuccinate (Ees-200): general benefit, Not a benefit

Ilosone · DIN 00210641 · 50mg/mL · oral liquid

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.Discontinued 2000-08-03 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ilosone · DIN 00210641 Manufacturer: Eli Lilly Canada Inc.; listing date 1996-10-01 Daily cost (source): $1.4260 Health Canada: Cancelled post market since 2000-08-03 · brand ILOSONE LIQUID 250MG/5ML · ATC J01FA01 ERYTHROMYCIN · form Suspension · route Oral · ingredients ERYTHROMYCIN (ERYTHROMYCIN ESTOLATE) 250 MG/5ML · company Eli lilly canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ilosone: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1284 · Verify on the e-Formulary ↗ (DIN 00210641)

Source record
DIN 00210641: Ilosone Raw flags: notABenefit=Y, sec3=Y Item: 081212007; group id 23; item number 0038; lccId None; manufacturer id LIL Source form: O/L; strength: 50mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00210641 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1284
Interchangeable products
Novo-Rythro Estolate · DIN 00262595 · $0.0713
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered

Matched class: 08:12:12 Erythromycins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): AZITHROMYCIN, CLARITHROMYCIN, ERYTHROMYCIN BASE, ERYTHROMYCIN ETHYLSUCCINATE 08:12:12 Erythromycins

AZITHROMYCIN

· 28 products · Listed, not a benefit (6), General benefit (21), Limited Use, codes 549 (1) · strengths: 100mg/5mL, 200mg/5mL, 250mg, 600mg · O/L-15mL Pk, O/L-22.5mL Pk, O/L-37.5mL Pk, Tab

CLARITHROMYCIN

· 25 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 500mg, 125mg/5mL, 250mg/5mL, 250mg · ER Tab, Ped Gran, Susp, Tab

ERYTHROMYCIN BASE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ERYTHROMYCIN ETHYLSUCCINATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg/mL, 80mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:12
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Ilosone: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026